Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

... and puts pipeline progress on the Web

January 1, 2007 | A version of this story appeared in Volume 85, Issue 1

Pfizer has launched a website where it will post the progress of compounds advancing through R&D. John L. LaMattina, president of Pfizer Global R&D, says the posting "will provide investors as well as the scientific and medical communities with more detail on our pipeline than ever before." The site, launched less than three weeks after Pfizer pulled its lead candidate, torcetrapib, from the clinic, includes Phase I compounds, late-stage medicines, and recently approved products.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.